Technical Analysis for BIIB - Biogen Idec Inc.

Grade Last Price % Change Price Change
grade C 292.04 0.00% 0.00
BIIB closed up 1.01 percent on Tuesday, June 19, 2018, on approximately normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical BIIB trend table...

Date Alert Name Type % Chg
Jun 18 MACD Bearish Signal Line Cross Bearish 1.01%
Jun 18 New Downtrend Bearish 1.01%
Jun 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.01%
Jun 18 Down 3 Days in a Row Weakness 1.01%
Jun 18 Gapped Down Weakness 1.01%
Jun 15 200 DMA Resistance Bearish -4.26%
Jun 15 Overbought Stochastic Strength -4.26%
Jun 14 Bearish Engulfing Bearish -4.46%
Jun 14 Downside 200 DMA Break Bearish -4.46%
Jun 14 Slingshot Bullish Bullish Swing Setup -4.46%

Older signals for BIIB ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
Is BIIB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 370.57
52 Week Low 249.17
Average Volume 1,652,389
200-Day Moving Average 305.934
50-Day Moving Average 281.3226
20-Day Moving Average 296.4105
10-Day Moving Average 302.406
Average True Range 7.3985
ADX 29.67
+DI 19.75
-DI 26.61
Chandelier Exit (Long, 3 ATRs ) 288.7145
Chandelier Exit (Short, 3 ATRs ) 298.6155
Upper Bollinger Band 313.8564
Lower Bollinger Band 278.9646
Percent B (%b) 0.37
BandWidth 11.771445
MACD Line 5.091
MACD Signal Line 6.6753
MACD Histogram -1.5843
Fundamentals Value
Market Cap 61.75 Billion
Num Shares 211 Million
EPS 15.24
Price-to-Earnings (P/E) Ratio 19.16
Price-to-Sales 5.55
Price-to-Book 5.61
PEG Ratio 2.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 307.00
Resistance 3 (R3) 306.66 301.33 304.50
Resistance 2 (R2) 301.33 297.52 301.50 303.67
Resistance 1 (R1) 296.69 295.17 299.01 297.03 302.84
Pivot Point 291.36 291.36 292.53 291.53 291.36
Support 1 (S1) 286.72 287.55 289.04 287.06 281.24
Support 2 (S2) 281.39 285.20 281.56 280.41
Support 3 (S3) 276.75 281.39 279.58
Support 4 (S4) 277.09